Pharma giant AstraZeneca announced plans to acquire FibroGen, Inc.’s China subsidiary for approximately $160 million. Expected to close mid-2025, the deal provides that FibroGen will receive an enterprise value of $85 million plus FibroGen’s net cash held in China at closing, currently estimated to be approximately $75...

NFTs – or non-fungible tokens – have taken the digital world by storm – or perhaps just a downloadable picture of a storm – promising to revolutionize not only the way we perceive, protect, purchase, and own digital assets,...